Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 432

1.

Antiprothrombin antibodies in patients with systemic lupus erythematosus or with primary antiphospholipid syndrome.

Salcido-Ochoa F, Cabiedes J, Alarcón-Segovia D, Cabral AR.

J Clin Rheumatol. 2002 Oct;8(5):251-5.

PMID:
17041380
2.

Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome.

Cesarman-Maus G, Ríos-Luna NP, Deora AB, Huang B, Villa R, Cravioto Mdel C, Alarcón-Segovia D, Sánchez-Guerrero J, Hajjar KA.

Blood. 2006 Jun 1;107(11):4375-82. Epub 2006 Feb 21.

3.

The different faces of shared autoimmunity.

Rodríguez-Reyna TS, Alarcón-Segovia D.

Autoimmun Rev. 2006 Feb;5(2):86-8. Epub 2005 Sep 21. Review.

PMID:
16431333
4.

Male systemic lupus erythematosus in a Latin-American inception cohort of 1214 patients.

Garcia MA, Marcos JC, Marcos AI, Pons-Estel BA, Wojdyla D, Arturi A, Babini JC, Catoggio LJ, Alarcon-Segovia D.

Lupus. 2005;14(12):938-46.

PMID:
16425573
5.

Overlap syndromes in the context of shared autoimmunity.

Rodríguez-Reyna TS, Alarcón-Segovia D.

Autoimmunity. 2005 May;38(3):219-23.

PMID:
16126510
6.

Shared autoimmunity: a concept for which the time has come.

Alarcón-Segovia D.

Autoimmunity. 2005 May;38(3):201-3. No abstract available.

PMID:
16126507
7.

Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort.

Alarcón-Segovia D, Alarcón-Riquelme ME, Cardiel MH, Caeiro F, Massardo L, Villa AR, Pons-Estel BA; Grupo Latinoamericano de Estudio del Lupus Eritematoso (GLADEL).

Arthritis Rheum. 2005 Apr;52(4):1138-47.

8.

[The future of medical investigation in Mexico].

de la Fuente JR, Martuscelli J, Alarcón-Segovia D.

Gac Med Mex. 2004 Sep-Oct;140(5):519-24. Review. Spanish.

PMID:
15559233
9.

Shared autoimmunity: the time has come.

Alarcón-Segovia D.

Curr Rheumatol Rep. 2004 Jun;6(3):171-4. Review. No abstract available.

PMID:
15134595
10.

Heterogeneity of antibodies to beta2-glycoprotein 1 from patients with systemic lupus erythematosus.

Cabral AR, Cabiedes J, Alarcón-Segovia D.

Lupus. 2004;13(3):182-7.

PMID:
15119547
11.

Systemic lupus erythematosus as a cause and prognostic factor of acute pancreatitis.

Pascual-Ramos V, Duarte-Rojo A, Villa AR, Hernández-Cruz B, Alarcón-Segovia D, Alcocer-Varela J, Robles-Díaz G.

J Rheumatol. 2004 Apr;31(4):707-12.

PMID:
15088295
12.

Neuroendocrine dopaminergic regulation of prolactin release in systemic lupus erythematosus: a possible role of lymphocyte-derived prolactin.

Méndez I, Alcocer-Varela J, Parra A, Lava-Zavala A, de la Cruz DA, Alarcón-Segovia D, Larrea F.

Lupus. 2004;13(1):45-53.

PMID:
14870917
13.

Prevalence and factors associated with fibromyalgia in Mexican patients with systemic lupus erythematosus.

Valencia-Flores M, Cardiel MH, Santiago V, Resendiz M, Castaño VA, Negrete O, Rosenberg C, García-Ramos G, Alcocer J, Alarcón-Segovia D.

Lupus. 2004;13(1):4-10.

PMID:
14870911
14.

The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among "Hispanics".

Pons-Estel BA, Catoggio LJ, Cardiel MH, Soriano ER, Gentiletti S, Villa AR, Abadi I, Caeiro F, Alvarellos A, Alarcón-Segovia D; Grupo Latinoamericano de Estudio del Lupus.

Medicine (Baltimore). 2004 Jan;83(1):1-17.

15.

Both risk alleles for FcgammaRIIA and FcgammaRIIIA are susceptibility factors for SLE: a unifying hypothesis.

Magnusson V, Johanneson B, Lima G, Odeberg J, Alarcón-Segovia D, Alarcón-Riquelme ME; SLE Genetics Collaboration Group.

Genes Immun. 2004 Mar;5(2):130-7.

PMID:
14737097
16.

Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo.

Strand V, Aranow C, Cardiel MH, Alarcón-Segovia D, Furie R, Sherrer Y, Tumlin J, Wallace DJ, Crawford B; LJP 394 Investigator Consortium.

Lupus. 2003;12(9):677-86.

PMID:
14514130
17.

The antiphospholipid story.

Alarcón-Segovia D.

J Rheumatol. 2003 Sep;30(9):1893-6. No abstract available.

PMID:
12966585
18.

Prophylaxis of the antiphospholipid syndrome: a consensus report.

Alarcón-Segovia D, Boffa MC, Branch W, Cervera R, Gharavi A, Khamashta M, Shoenfeld Y, Wilson W, Roubey R.

Lupus. 2003;12(7):499-503. Review.

PMID:
12892387
19.

Antibody penetration into living cells: pathogenic, preventive and immuno-therapeutic implications.

Ruiz-Argüelles A, Rivadeneyra-Espinoza L, Alarcón-Segovia D.

Curr Pharm Des. 2003;9(23):1881-7. Review.

PMID:
12871192
20.

[DNA as an autoantigen].

Alarcón Segovia D.

Rev Invest Clin. 2003 Mar-Apr;55(2):124-7. Review. Spanish. No abstract available.

PMID:
12827914
21.

Immunoregulatory defects in patients with systemic lupus erythematosus in clinical remission.

Crispin JC, Alcocer-Varela J, de Pablo P, Martínez A, Richaud-Patin Y, Alarcón-Segovia D.

Lupus. 2003;12(5):386-93.

PMID:
12765302
22.

Valine/valine genotype at position 247 of the beta2-glycoprotein I gene in Mexican patients with primary antiphospholipid syndrome: association with anti-beta2-glycoprotein I antibodies.

Prieto GA, Cabral AR, Zapata-Zuñiga M, Simón AJ, Villa AR, Alarcón-Segovia D, Cabiedes J.

Arthritis Rheum. 2003 Feb;48(2):471-4.

23.

LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study.

Alarcón-Segovia D, Tumlin JA, Furie RA, McKay JD, Cardiel MH, Strand V, Bagin RG, Linnik MD, Hepburn B; LJP 394 Investigator Consortium.

Arthritis Rheum. 2003 Feb;48(2):442-54.

24.

Anticardiolipin and anti-beta2-glycoprotein-I antibodies in hypertensive disorders of pregnancy.

Valdés-Macho E, Cabiedes J, Villa AR, Cabral AR, Alarcón-Segovia D.

Arch Med Res. 2002 Sep-Oct;33(5):460-5.

PMID:
12459316
25.

A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans.

Prokunina L, Castillejo-López C, Oberg F, Gunnarsson I, Berg L, Magnusson V, Brookes AJ, Tentler D, Kristjansdóttir H, Gröndal G, Bolstad AI, Svenungsson E, Lundberg I, Sturfelt G, Jönssen A, Truedsson L, Lima G, Alcocer-Varela J, Jonsson R, Gyllensten UB, Harley JB, Alarcón-Segovia D, Steinsson K, Alarcón-Riquelme ME.

Nat Genet. 2002 Dec;32(4):666-9. Epub 2002 Oct 28.

PMID:
12402038
26.

A major susceptibility locus for systemic lupus erythemathosus maps to chromosome 1q31.

Johanneson B, Lima G, von Salomé J, Alarcón-Segovia D, Alarcón-Riquelme ME; Collaborative Group on the Genetics of SLE, The BIOMED II Collaboration on the Genetics of SLE and Sjögrens syndrome.

Am J Hum Genet. 2002 Nov;71(5):1060-71. Epub 2002 Oct 8.

27.

Prevalence of battering among 1780 outpatients at an internal medicine institution in Mexico.

Díaz-Olavarrieta C, Ellertson C, Paz F, de Leon SP, Alarcon-Segovia D.

Soc Sci Med. 2002 Nov;55(9):1589-602.

PMID:
12297245
28.

Characterization of anti-phosphatidylcholine polyreactive natural autoantibodies from normal human subjects.

Cabiedes J, Cabral AR, López-Mendoza AT, Cordero-Esperón HA, Huerta MT, Alarcón-Segovia D.

J Autoimmun. 2002 Mar;18(2):181-90.

PMID:
11908950
29.

Anti-cardiolipin, anti-cardiolipin plus bovine, or human beta(2)glycoprotein-I and anti-human beta(2)glycoprotein-I antibodies in a healthy infant population.

Cabiedes J, Trejo-Hernández J, Loredo-Abdalá A, Castilla-Serna L, López-Mendoza AT, Cordero-Esperón HA, Huerta MT, Cabral AR, Alarcón-Segovia D.

Arch Med Res. 2002 Mar-Apr;33(2):175-9.

PMID:
11886718
30.

A patient who developed dermatomyositis after suffering for 7 years from rheumatoid arthritis.

Alarcón-Segovia D.

Rheumatol Int. 2002 Jan;21(4):167. No abstract available.

PMID:
11843175
31.

Splenectomy has a limited role in the management of lupus with thrombocytopenia.

Alarcon-Segovia D.

J Rheumatol. 2002 Jan;29(1):1-2. No abstract available.

PMID:
11824944
32.

Distribution of class I and class III MHC antigens in the Tarasco Amerindians.

Loeza F, Vargas-Alarcón G, Andrade F, Vergara Y, Rodríguez-Pérez JM, Ruiz-Morales JA, Alarcón-Segovia D, Granados J.

Hum Immunol. 2002 Feb;63(2):143-8.

PMID:
11821162
33.

Novel facts about an old marker: the LE cell.

Ruiz-Argüelles A, Alarcón-Segovia D.

Scand J Clin Lab Invest Suppl. 2001;235:31-7. Review.

PMID:
11712690
34.

The recovery of self tolerance in SLE.

Alarcón-Segovia D.

Lupus. 2001;10(8):521-2. Review. No abstract available.

PMID:
11530991
35.

Class II allele and haplotype frequencies in Mexican systemic lupus erythematosus patients: the relevance of considering homologous chromosomes in determining susceptibility.

Vargas-Alarcón G, Salgado N, Granados J, Gómez-Casado E, Martinez-Laso J, Alcocer-Varela J, Arnaiz-Villena A, Alarcón-Segovia D.

Hum Immunol. 2001 Aug;62(8):814-20.

PMID:
11476905
36.

Antinuclear antibodies: to penetrate or not to penetrate, that was the question.

Alarcón-Segovia D.

Lupus. 2001;10(5):315-8. Review. No abstract available.

PMID:
11403260
37.

The predestination of autoantibodies.

Alarcón-Segovia D.

Curr Rheumatol Rep. 2001 Jun;3(3):173-4. No abstract available.

PMID:
11352785
38.

The future of treatment for systemic lupus erythematosus.

Alarcón-Segovia D.

Isr Med Assoc J. 2001 Feb;3(2):127-30. Review.

39.

Penetration of autoantibodies into living cells, 2000.

Ruiz-Argüelles A, Alarcón-Segovia D.

Isr Med Assoc J. 2001 Feb;3(2):121-6. Review.

40.

Survival of Mexican patients with systemic lupus erythematosus.

Alarcon-Segovia D, Drenkard C, Villa AR.

Rheumatology (Oxford). 2001 Feb;40(2):228-9. No abstract available.

PMID:
11257165
41.

Association analysis with microsatellite and SNP markers does not support the involvement of BCL-2 in systemic lupus erythematosus in Mexican and Swedish patients and their families.

Johansson C, Castillejo-López C, Johanneson B, Svenungsson E, Gunnarsson I, Frostegård J, Sturfelt G, Truedsson L, Löfström B, Alcocer-Varela J, Lundberg I, Gyllensten UB, Alarcón-Segovia D, Alarcón-Riquelme ME.

Genes Immun. 2000 Aug;1(6):380-5.

42.

Fine mapping of the SLEB2 locus involved in susceptibility to systemic lupus erythematosus.

Magnusson V, Lindqvist AK, Castillejo-López C, Kristjánsdottir H, Steinsson K, Gröndal G, Sturfelt G, Truedsson L, Svenungsson E, Lundberg I, Gunnarsson I, Bolstad AI, Haga HJ, Jonsson R, Klareskog L, Alcocer-Varela J, Alarcón-Segovia D, Terwilliger JD, Gyllensten UB, Alarcón-Riquelme ME.

Genomics. 2000 Dec 15;70(3):307-14.

PMID:
11161781
43.

Are there "Attenuated" Forms of Evans Syndrome?

Ruiz-Argüelles GJ, López-Martínez B, Estrada E, Ruiz-Delgado GJ, Alarcón-Segovia D.

Hematology. 2001;6(6):429-32. doi: 10.1080/10245332.2001.11746598.

PMID:
27405699
44.

Vasculitis in the connective tissue diseases.

Felipe Flores-Suárez L, Alarcón-Segovia D.

Curr Rheumatol Rep. 2000 Oct;2(5):396-401. Review.

PMID:
11123089
45.

Anetoderma in systemic lupus erythematosus: relationship to antiphospholipid antibodies.

Montilla C, Alarcón-Segovia D.

Lupus. 2000;9(7):545-7.

PMID:
11035422
46.

Long-term prognosis of antiphospholipid syndrome in patients with systemic lupus erythematosus.

Alarcón-Segovia D, Pérez-Ruiz A, Villa AR.

J Autoimmun. 2000 Sep;15(2):157-61. Review. No abstract available.

PMID:
10968903
47.

Vasculitis and the antiphospholipid syndrome.

Alarcón-Segovia D, Drenkard C.

Rheumatology (Oxford). 2000 Aug;39(8):922-3. No abstract available.

PMID:
10952752
48.

Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus.

Llorente L, Richaud-Patin Y, García-Padilla C, Claret E, Jakez-Ocampo J, Cardiel MH, Alcocer-Varela J, Grangeot-Keros L, Alarcón-Segovia D, Wijdenes J, Galanaud P, Emilie D.

Arthritis Rheum. 2000 Aug;43(8):1790-800.

49.

Malignant neoplasms in autoimmune rheumatic diseases: examination of the risk of developing a malignancy among five different rheumatic diseases in one institution.

Villa AR, Kraus A, Jiménez-Corona A, Sandino S, Velázquez-González A, Granados J, Alarcón-Segovia D.

J Clin Rheumatol. 2000 Aug;6(4):176-83.

PMID:
19078467
50.

The new prognosis of systemic lupus erythematosus: treatment-free remission and decreased mortality and morbidity.

Drenkard C, Alarcón-Segovia D.

Isr Med Assoc J. 2000 May;2(5):382-7. Review. No abstract available.

Supplemental Content

Loading ...
Support Center